| Generic name | Acalabrutinib |
| Brand name(s), other common name(s) | CalquenceTM |
| Drug type | BTK inhibitor |
| How the drug is given | By mouth |
Indications and Usage
Acalabrutinib is a kinase inhibitor indicated for the treatment of adult patients with
- Mantle cell lymphoma (MCL) who have received at least one prior therapy
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
- Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Side effects needing medical attention
Headache, diarrhea, bruising, fatigue and muscle pain (myalgia), and reduced levels of red blood cells (anemia), platelets (thrombocytopenia) and neutrophils (neutropenia) in the blood.
Serious side effects include bleeding (hemorrhage), infections and irregular heartbeat (atrial fibrillation). Additional cancers, known as second primary malignancies, have occurred in some patients taking Calquence.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.